Searched for
GLAXOSMITHKLINE PHARMA
More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 22%As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- GSK's Calpol a well-known trademark: High CourtThe Delhi High Court has recognized GlaxoSmithKline Pharmaceuticals' pain and fever medicine, Calpol, as a well-known trademark. This desig...
- Bombay HC backs GSK in Paxil trademark row against Shreya Life SciencesThe Indian subsidiary of the UK-based GSK PLC had urged the court to cancel the mark used by the local company in pharmaceutical and medici...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosolPharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks...
- I-Sec upgrades GlaxoSmithKline Pharma to Add, lowers target price to Rs 2,250ICICI Securities has raised its rating on GlaxoSmithKline Pharmaceuticals to Add from Hold with a new target price of Rs 2250. GSK Pharma's...
- GlaxoSmithKline Pharma Q4 Results: Firm posts net loss at Rs 55 croreRevenue from operations rose to Rs 810 crore for the fourth quarter compared to Rs 744 crore in the year-ago period, GlaxoSmithKline Pharma...
- GlaxoSmithKline Pharma Q2 net dips 25 per cent at Rs 96 croreThe company had posted a net profit of Rs 128.67 crore for the same period a year ago, GlaxoSmithKline Pharmaceuticals said in a filing to ...
- GSK Pharma to transfer cancer drug portfolio to Novartis armGlaxoSmithKline Pharmaceuticals board approved transfer of its cancer drugs portfolio to an arm of Novartis in India in return for acquirin...
- GlaxoSmithKline Pharma Q3 net profit declines 61% to Rs 45 croreGlaxoSmithKline Pharmaceuticals today reported a 61.24 per cent decline in its net profit at Rs 45.30 crore for the October-December period.
- FIPB clears GlaxoSmithKline's Rs 6,400 cr FDI proposalFIPB today cleared Rs 6,400 crore FDI proposal of GlaxoSmithKline to acquire additional 24.33 per cent stake in its India arm.
- FIPB to decide on GlaxoSmithKline, other pharma FDI proposalsFIPB will take up tomorrow GlaxoSmithKline's Rs 6,400 crore FDI plan, the largest foreign investment proposal in the pharma sector this fis...
- GlaxoSmithKline seeks FIPB nod to hike stake in Indian armGlaxoSmithKline has approached the FIPB to hike stake in its domestic arm by buying 24.33 per cent for an estimated Rs 6,400 crore.
- GSK's open offer for buying stake in Indian arm from February 7-21GlaxoSmithKline Plc's Rs 6,389.02 crore open offer to pick up 24.33 per cent stake in its Indian arm GlaxoSmithKline Pharma will start from...
- GlaxoSmithKline Pharma: Supply woes, new drug policy cause for concernUnder-performance is likely to continue in the quarter to June since the company expects the supply constraints to ease only by the end of ...
- GlaxoSmithKline FY10 net profit up 10.37 pc to Rs 560.57 crGlaxoSmithKline Pharmaceuticals today said its consolidated net profit rose by 10.37 per cent to Rs 560.57 crore for the year ended Decembe...
- GSK Pharma: New product pipeline to boost sales growthThe company, which is among the top three players in the domestic market, posted an improved performance across all its business segments o...
- Ranbaxy's pact with GSK gives it scope for drug devtRanbaxy Labs had earlier entered into an agreement with GlaxoSmithKline, under which the domestic pharma major was responsible for selectin...
Load More
